HLA G-modified cells and methods
US10502738B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 16, 2017 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Jun 16, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/245
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.